Analyst Price Targets — FATE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 8, 2026 10:58 am | Debjit Chattopadhyay | H.C. Wainwright | $7.00 | $1.98 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE) |
| May 19, 2026 7:14 pm | — | Jefferies | $4.00 | $1.89 | TheFly | Fate Therapeutics assumed with a Buy at Jefferies |
| March 6, 2025 11:51 am | — | Stifel Nicolaus | $3.00 | $1.04 | TheFly | Fate Therapeutics price target lowered to $3 from $5 at Stifel |
| November 13, 2024 1:53 pm | Etzer Darout | BMO Capital | $5.00 | $3.37 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital |
| August 14, 2024 8:37 am | Benjamin Burnett | Stifel Nicolaus | $5.00 | $3.27 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at Stifel |
| June 17, 2024 3:50 am | Edward Tenthoff | Piper Sandler | $6.00 | $3.61 | StreetInsider | Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight |
| May 16, 2024 6:44 am | Debjit Chattopadhyay | H.C. Wainwright | $5.00 | $4.24 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright |
| May 10, 2024 8:14 am | Edward Tenthoff | Piper Sandler | $4.00 | $3.88 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler |
| May 10, 2024 7:55 am | Etzer Darout | BMO Capital | $6.00 | $3.87 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $6 at BMO Capital |
| May 10, 2024 7:28 am | Bill Maughan | Canaccord Genuity | $9.00 | $3.90 | TheFly | Fate Therapeutics price target lowered to $9 from $11 at Canaccord |
Latest News for FATE
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate,…
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate,…
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the third quarter of 2026.
Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the stock. They've reported broader autoimmune data and are now planning RECLAIM-LN. Unfortunately, I think their recent removal from the Russell 3000 index could be a near-term headwind for the stock price itself.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FATE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.